Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • Anticancer Research
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • In Vivo
    • Anticancer Research
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
In Vivo
  • Other Publications
    • In Vivo
    • Anticancer Research
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
In Vivo

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • Anticancer Research
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Visit iiar on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Radiation to the Primary Tumor in Metastatic Anaplastic Thyroid Cancer

TERESA AUGUSTIN, DMYTRO OLIINYK, JOSEFINE RAUCH, VIKTORIA FLORENTINE KOEHLER, CHRISTINE SPITZWEG, CLAUS BELKA and LUKAS KÄSMANN
In Vivo January 2021, 35 (1) 461-465; DOI: https://doi.org/10.21873/invivo.12279
TERESA AUGUSTIN
1Department of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DMYTRO OLIINYK
1Department of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JOSEFINE RAUCH
1Department of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
VIKTORIA FLORENTINE KOEHLER
2Department of Internal Medicine IV, University Hospital, LMU Munich, Munich, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CHRISTINE SPITZWEG
2Department of Internal Medicine IV, University Hospital, LMU Munich, Munich, Germany;
3German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CLAUS BELKA
1Department of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany;
3German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
LUKAS KÄSMANN
1Department of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany;
3German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: lukas.kaesmann@med.uni-muenchen.de
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background/Aim: Metastatic anaplastic thyroid cancer is associated with a dismal prognosis. We evaluated outcome and prognostic factors in patients receiving radiation to the primary tumor in metastatic anaplastic thyroid cancer (ATC). Patients and Methods: All consecutive patients with metastatic ATC (n=20) undergoing irradiation between 2009 and 2019 for anaplastic thyroid cancer were investigated. Results: Median survival time and median progression-free survival were 2 (range=1-22) and 2 (1-20) months. In univariate analyses, surgery, concurrent or sequential chemotherapy and higher radiation dose escalation (>39 Gy) were correlated with longer overall survival (p=0.005, p=0.018 and p=0.038), respectively. Karnofsky performance status >70% showed a trend of longer survival time (p=0.062). Limited metastatic disease, surgery and concurrent/sequential chemotherapy are correlated with longer progression-free survival times (p=0.043, p=0.024 and p=0.039), respectively. Conclusion: Radiation to the primary tumor in metastatic anaplastic thyroid cancer is safe and offers durable local control. Treatment intensification including concurrent or sequential chemotherapy and radiation dose escalation were associated with longer survival rates and should be considered in selected patients with metastatic disease.

  • ATC
  • anaplastic thyroid cancer
  • metastatic
  • irradiation
  • survival

Anaplastic thyroid cancer (ATC) is an orphan disease with a dismal prognosis (1-6). Median survival times range between 3 and 16 months depending on Union for International Cancer Control tumor–node–metastasis (UICC TNM) stage (7-9). National and international guidelines recommend that ATC patients with stage IVA/B should be considered for radical surgery if negative pathological margins (R0/R1) can be achieved and should be avoided if there is a high chance of gross residual disease (R2) (2-5).

However, the majority of ATC patients are considered to be inoperable due to locally advanced disease and comorbidities. So far, no standard treatment regimen has been successfully established in stage IVC (4, 5).

Local radiotherapy (RT) should always be considered as part of the initial multimodal therapy approach to improve overall survival (OS) (6, 9-11) and provide local and symptom control in order to maintain quality of life. However, it is a matter of debate if local RT is still recommended in metastatic disease where aggressive systemic therapy has to be weighed against benefits from local control and limited systemic approaches.

The aim of the present study was to evaluate outcome and prognostic factors in patients receiving radiation to primary tumor of metastatic anaplastic thyroid cancer.

Patients and Methods

Study population. The medical charts of 20 consecutive patients with metastatic anaplastic thyroid cancer treated with irradiation to primary tumor between 2009 and 2019 were reviewed. Patient and treatment characteristics are summarized in Table I. The Institutional Research Ethical Review Board approved the study (approval number: 19-885).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

Patient- and treatment-related characteristics.

Diagnostics and treatment. ATC was histologically confirmed in all patients and diagnosed as stage IVC according to the revised 8th edition of the UICC TNM classification (7). A lobectomy was performed in two (10%) patients and three (15%) patients had received a total thyroidectomy. Chemotherapy was administered in 9 (45%) patients, of which 5 (25%) patients received concurrent chemotherapy with carboplatin AUC 2 with Paclitaxel 50 mg/m2 weekly, which has been the standard at our Institution in the recent years, and 3 patients (15%) received concurrent chemotherapy with doxorubicin (10 or 20 mg/m2) weekly. Sequential chemotherapy (doxorubicin/cisplatin) was administered in one (5%) patient before radiation. Three-dimensional conformal radiotherapy (3D-CRT) technique was administered in 13 (65%) patients and 7 (35%) patients received intensity modulated radiation therapy (IMRT). The median radiation dose in equivalent dose in 2 Gy fractions (EQD2) was 42 (range=5-70) Gy. Seven potential patient- and treatment-related features, namely age, gender, Karnofsky performance status (KPS), number of involved metastatic sites, surgery, concurrent and sequential chemotherapy and radiation dose escalation were analysed for their impact on OS and progression-free survival (PFS). Treatment-related side-effects were evaluated using Common Terminology Criteria for Adverse events (CTCAE) version 4.

Statistical analysis. Statistical analyses were performed using SPSS statistics 25 (IBM, New York City, NY, SA). The log-rank test was used to compare subgroups. All significant variables in univariate analysis were included in a multivariate analysis (Cox regression). OS was defined as the time between diagnosis and death. PFS was defined as the time between diagnosis and the development of local relapse, distant metastases or death from all causes.

For all statistical analyses, a p-value <0.05 was considered statistically significant.

Results

Median survival time was 2 (range=1-22) months. Survival at 1, 3 and 12 months of the entire cohort was 65, 30 and 5%, respectively. No local progression was observed in the first 12 months after radiotherapy. Progression-free survival was 2 (range=1-20) months. In univariate analyses, surgery (p=0.005), sequential or concurrent chemotherapy (p=0.018) and radiation dose escalation (>39 Gy, p=0.038) resulted in improved OS (Table II), respectively. Karnofsky performance status >70% showed a trend for longer survival time (p=0.062). On multivariate analysis, no factor achieved significance for OS. Limited metastatic sites (1 vs. 2-4 sites, p=0.043), surgery (p=0.024) and chemotherapy (p=0.039) are associated with improved PFS (Table III). On multivariate analysis for PFS no factor achieved significance.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table II.

Uni- and multivariate analyses of overall survival.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table III.

Uni- and multivariate analyses of progression-free survival.

Acute toxicity (grade 3) of dysphagia, dyspnea, dermatitis, mucositis and dysphonia were found in 20%, 30%, 5%, 5% and 10% of patients, respectively. CTCAE grade 4/5 was not observed.

Discussion

The treatment of patients with metastatic ATC should be planned in a multidisciplinary expert team also considering prognostic factors, which allow estimating the patient’s prognosis (1, 10, 12). Systemic treatment remains the main treatment of metastatic ATC, but usually results in low response rates and significant toxicities. Treatment with paclitaxel or doxorubicin or combined treatment approaches (e.g. carboplatin/paclitaxel, docetaxel/doxorubicin) are recommended (5).

Tumor-related complications such as airway or esophageal obstruction, hemorrhage and vocal cord paralysis can be lethal and should be taken into account for shared-decision making (2-5). Therefore, prognostic factors that indicate the effect of radiotherapy on local control and survival are important to identify high-risk patients who do not achieve a satisfying outcome and may benefit from treatment intensification such as radiation dose escalation or concurrent chemotherapy.

Several studies investigated potential prognostic factors in ATC such as age, presence of acute symptoms, leukocytosis, large local tumors, resection status and distant metastasis (1, 13, 14). Data about prognostic factors in stage IVC are still limited (8, 13, 15).

The present study aimed to evaluate outcome and prognostic factors in patients with metastatic anaplastic thyroid cancer that received radiation to the primary tumor. As a result, cervical irradiation appears to be effective and offers durable local control of the disease. In our analysis surgery, chemotherapy (carboplatin/paclitaxel or doxorubicin) and radiation dose escalation (>39 Gy) were correlated with longer OS. This is consistent with the findings by Wendler et al. who reported a significant association of multimodal treatment approaches with a survival benefit in ATC stage IVC patients (1) as well as the study of Sugitani et al. with 223 ATC patients in stage IVC which found that radical surgery (p=0.0002), dose escalated radiotherapy (≥40 Gy) (p<0.0001) and chemotherapy (p<0.0001) were correlated with longer survival rates (13).

A National Cancer Data Base (NCDB) study of 606 patients with ATC stage IVC found a dose-survival correlation in patients receiving 60 to 75 Gy compared to 45 to 59.9 Gy (15). These data go along with the findings of our present study.

Despite local and symptom control, pattern of failure in ATC tends to be metastatic progression, which is consistent with our study (16). We found that a limited number of metastatic sites (‘oligometastatic disease’) appears to be a prognostic factor for PFS (see Table III) and that these patients may benefit from more aggressive treatment approaches which offer reliable local control and longer OS.

Treatment-related side-effects were manageable according to our study. However, treatment intensification should be discussed in multidisciplinary teams including surgeons, radiation oncologists, endocrinologists, medical oncologists, and palliative care teams.

Due to a substantial increase of druggable tumor-specific molecular aberrations in the past decade, molecular profiling has become an integral part of diagnosis and therapy in oncology, gaining more and more importance in the treatment of ATC. The most frequently investigated single agents or agents in combined treatment approaches are multikinase inhibitors (e.g. lenvatinib, sorafenib), PI3K/mTOR inhibitors (e.g. everolismus), vascular-targeting agents (e.g. fosbretabulin), BRAF-inhibitors (e.g. dabrafenib) and checkpoint inhibitors (e.g. pembrolizumab, spartalizumab) (17-23).

The combination of BRAF-inhibitor dabrafenib and MEK-inhibitor trametinib achieved approval by the Food and Drug Administration (FDA) in 2018 based on the promising results of a phase II study comprising BRAFV600E-mutated ATC (21). The overall response rate in the ATC-subgroup was 61%, of which 57% experienced a partial and 4% a complete response. In addition, several checkpoint inhibitors such as pembrolizumab, spartalizumab and durvalumab alone or in combination with conventional treatment regimens (RT, ChT) have been investigated (22-24).

Recently, the combination of lenvatinib with pembrolizumab has achieved excellent results in metastatic ATC (25). However, larger trials investigating this combined treatment approach are ongoing and highly anticipated (26).

Several limitations must be considered in interpreting the results of our study such as the retrospective design and, therefore, a risk of including hidden selection biases. In addition, the patient cohort is relatively small with a long recruitment period. However, ATC is an orphan disease and stage IVC is associated with a dismal prognosis. We found that local irradiation offers durable local control in metastatic ATC patients and identified several prognostic factors in this setting. As a result, we are convinced that our study may help physicians to tailor personalized treatment approaches.

In summary, treatment-related side-effects appear to be manageable and therapy intensification including concurrent or sequential chemotherapy and radiation dose escalation were correlated with longer survival rates.

Conclusion

Radiation to the primary tumor in metastatic anaplastic thyroid cancer is safe and offers durable local control. Treatment intensification including concurrent or sequential chemotherapy and radiation dose escalation were correlated with longer survival rates and should be considered in selected patients with metastatic disease.

Footnotes

  • Authors’ Contributions

    Conception and Design: L.K., T.A., D.O.; Administrative support: C.B., C.S., L.K.; Provision of study materials or patients: L.K., C.S., C.B., J.R.; Collection and assembly of data: L.K., T.A., D.O.; Data analysis and interpretation: L.K., T.A., D.O.; Manuscript writing: All authors; Final approval of manuscript: All Authors.

  • This article is freely accessible online.

  • Conflicts of Interest

    There are no conflicts of interest to declare regarding this study.

  • Received November 16, 2020.
  • Revision received November 29, 2020.
  • Accepted December 1, 2020.
  • Copyright© 2021, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved

References

  1. ↵
    1. Wendler J,
    2. Kroiss M,
    3. Gast K,
    4. Kreissl MC,
    5. Allelein S,
    6. Lichtenauer U,
    7. Blaser R,
    8. Spitzweg C,
    9. Fassnacht M and
    10. Schott M
    : Clinical presentation, treatment and outcome of anaplastic thyroid carcinoma: results of a multicenter study in Germany. Eur J Endocrinol 175(6): 521-529, 2016. PMID: 27926471. DOI: 10.1530/EJE-16-0574
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Smallridge RC,
    2. Ain KB,
    3. Asa SL,
    4. Bible KC,
    5. Brierley JD,
    6. Burman KD,
    7. Kebebew E,
    8. Lee NY,
    9. Nikiforov YE and
    10. Rosenthal MS
    : American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid 22(11): 1104-1139, 2012. PMID: 23130564. DOI: 10.1089/thy.2012.0302
    OpenUrlCrossRefPubMed
    1. Perros P,
    2. Boelaert K,
    3. Colley S,
    4. Evans C,
    5. Evans RM,
    6. Gerrard BA G,
    7. Gilbert J,
    8. Harrison B,
    9. Johnson SJ and
    10. Giles TE
    : Guidelines for the management of thyroid cancer. Clin Endocrinol (Oxf) 81(Suppl 1): 1-122, 2014. PMID: 24989897. DOI: 10.1111/cen.12515
    OpenUrlCrossRefPubMed
  3. ↵
    1. Haddad R,
    2. Lydiatt W,
    3. Bischoff L,
    4. Busaidy N,
    5. Byrd D,
    6. Callender G,
    7. Dickson P,
    8. Duh Q,
    9. Ehya H and
    10. Haymart M
    : NCCN clinical practive guidelines in oncology (NCCN guidelines): thyroid carcinoma. Version 1, 2019. NCCN 2019. Available at: https://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf [Last accessed July 1, 2019]
  4. ↵
    1. Filetti S,
    2. Durante C,
    3. Hartl D,
    4. Leboulleux S,
    5. Locati L,
    6. Newbold K,
    7. Papotti M,
    8. Berruti A
    : Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 30(12): 1856-1883, 2019. PMID: 31549998. DOI: 10.1093/annonc/mdz400
    OpenUrlCrossRefPubMed
  5. ↵
    1. Oliinyk D,
    2. Augustin T,
    3. Koehler VF,
    4. Rauch J,
    5. Belka C,
    6. Spitzweg C and
    7. Käsmann L
    : Hypofractionated radiotherapy for anaplastic thyroid cancer: Systematic review and pooled analysis. Cancers 12(9): 2506, 2020. PMID: 32899355. DOI: 10.3390/cancers12092506
    OpenUrlCrossRef
  6. ↵
    1. Brierley JD,
    2. Gospodarowicz MK and
    3. Wittekind C
    : TNM classification of malignant tumours. Chichester, West Sussex, UK Hoboken, Wiley Blackwell/John Wiley & Sons, Inc, 2017.
  7. ↵
    1. Onoda N,
    2. Sugitani I,
    3. Ito K,
    4. Suzuki A,
    5. Higashiyama T,
    6. Fukumori T,
    7. Suganuma N,
    8. Masudo K,
    9. Nakayama H and
    10. Uno A
    : Evaluation of the 8th edition TNM classification for anaplastic thyroid carcinoma. Cancers 12(3): 552, 2020. PMID: 32120853. DOI: 10.3390/cancers12030552
    OpenUrlCrossRef
  8. ↵
    1. Augustin T,
    2. Oliinyk D,
    3. Köhler VF,
    4. Rauch J,
    5. Belka C,
    6. Spitzweg C and
    7. Käsmann L
    : Clinical outcome and toxicity in the treatment of anaplastic thyroid cancer in elderly patients. J Clin Med 9(10): 3231, 2020. PMID: 33050286. DOI: 10.3390/jcm9103231
    OpenUrlCrossRef
  9. ↵
    1. Käsmann L,
    2. Bolm L,
    3. Janssen S and
    4. Rades D
    : Prognostic factors for survival in patients treated with multimodal therapy for anaplastic thyroid cancer. Anticancer Res 36(9): 4697-4700, 2016. PMID: 27630315. DOI: 10.21873/anticancerres.11023
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Fan D,
    2. Ma J,
    3. Bell AC,
    4. Groen AH,
    5. Olsen KS,
    6. Lok BH,
    7. Leeman JE,
    8. Anderson E,
    9. Riaz N and
    10. McBride S
    : Outcomes of multimodal therapy in a large series of patients with anaplastic thyroid cancer. Cancer 126(2): 444-452, 2020. PMID: 31593317. DOI: 10.1002/cncr.32548
    OpenUrlCrossRef
  11. ↵
    1. Rades D,
    2. Janssen S,
    3. Käsmann L,
    4. Bolm L and
    5. Schild SE
    : Outcomes after irradiation of epidural spinal cord compression due to metastatic thyroid cancer. Anticancer Res 36(4): 2035-2039, 2016. PMID: 27069199.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Sugitani I,
    2. Miyauchi A,
    3. Sugino K,
    4. Okamoto T,
    5. Yoshida A and
    6. Suzuki S
    : Prognostic factors and treatment outcomes for anaplastic thyroid carcinoma: ATC Research Consortium of Japan cohort study of 677 patients. World J Surg 36(6): 1247-1254, 2012. PMID: 22311136. DOI: 10.1007/s00268-012-1437-z
    OpenUrlCrossRefPubMed
  13. ↵
    1. Käsmann L,
    2. Eze C and
    3. Manapov F
    : Stereotactic body radiation therapy (SBRT) combined with immune check-point inhibition (ICI) in advanced lung cancer: Which metastatic site should be irradiated to induce immunogenic cell death? Int J Radiat Oncol Biol Phys 108(1): 225-226, 2020. PMID: 32414625. DOI: 10.1016/j.ijrobp.2020.04.002
    OpenUrlCrossRef
  14. ↵
    1. Pezzi TA,
    2. Mohamed AS,
    3. Sheu T,
    4. Blanchard P,
    5. Sandulache VC,
    6. Lai SY,
    7. Cabanillas ME,
    8. Williams MD,
    9. Pezzi CM and
    10. Lu C
    : Radiation therapy dose is associated with improved survival for unresected anaplastic thyroid carcinoma: outcomes from the National Cancer Data Base. Cancer 123(9): 1653-1661, 2017. PMID: 28026871. DOI: 10.1002/cncr.30493
    OpenUrlCrossRef
  15. ↵
    1. Rao SN,
    2. Zafereo M,
    3. Dadu R,
    4. Busaidy NL,
    5. Hess K,
    6. Cote GJ,
    7. Williams MD,
    8. William WN,
    9. Sandulache V and
    10. Gross N
    : Patterns of treatment failure in anaplastic thyroid carcinoma. Thyroid 27(5): 672-681, 2017. PMID: 28068873. DOI: 10.1089/thy.2016.0395
    OpenUrlCrossRefPubMed
  16. ↵
    1. Savvides P,
    2. Nagaiah G,
    3. Lavertu P,
    4. Fu P,
    5. Wright JJ,
    6. Chapman R,
    7. Wasman J,
    8. Dowlati A and
    9. Remick SC
    : Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid. Thyroid 23(5): 600-604, 2013. PMID: 23113752. DOI: 10.1089/thy.2012.0103
    OpenUrlCrossRefPubMed
    1. Tahara M,
    2. Kiyota N,
    3. Yamazaki T,
    4. Chayahara N,
    5. Nakano K,
    6. Inagaki L,
    7. Toda K,
    8. Enokida T,
    9. Minami H and
    10. Imamura Y
    : Lenvatinib for anaplastic thyroid cancer. Front Oncol 7: 25, 2017. PMID: 28299283. DOI: 10.3389/fonc.2017.00025
    OpenUrlCrossRefPubMed
    1. Hanna GJ,
    2. Busaidy NL,
    3. Chau NG,
    4. Wirth LJ,
    5. Barletta JA,
    6. Calles A,
    7. Haddad RI,
    8. Kraft S,
    9. Cabanillas ME and
    10. Rabinowits G
    : Genomic correlates of response to everolimus in aggressive radioiodine-refractory thyroid cancer: a phase II study. Clin Cancer Res 24(7): 1546-1553, 2018. PMID: 29301825. DOI: 10.1158/1078-0432.CCR-17-2297
    OpenUrlAbstract/FREE Full Text
  17. ↵
    1. Mooney CJ,
    2. Nagaiah G,
    3. Fu P,
    4. Wasman JK,
    5. Cooney MM,
    6. Savvides PS,
    7. Bokar JA,
    8. Dowlati A,
    9. Wang D and
    10. Agarwala SS
    : A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome. Thyroid 19(3): 233-240, 2019. PMID: 19265494. DOI: 10.1089/thy.2008.0321
    OpenUrlCrossRef
  18. ↵
    1. Subbiah V,
    2. Kreitman RJ,
    3. Wainberg ZA,
    4. Cho JY,
    5. Schellens JH,
    6. Soria JC,
    7. Wen PY,
    8. Zielinski C,
    9. Cabanillas ME and
    10. Urbanowitz G
    : Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600–mutant anaplastic thyroid cancer. J Clin Oncol 36(1): 7, 2018. PMID: 29072975. DOI: 10.1200/JCO.2017.73.6785
    OpenUrlCrossRefPubMed
  19. ↵
    1. Chintakuntlawar AV,
    2. Yin J,
    3. Foote RL,
    4. Kasperbauer JL,
    5. Rivera M,
    6. Asmus E,
    7. Garces NI,
    8. Janus JR,
    9. Liu M and
    10. Ma DJ
    : A phase 2 study of pembrolizumab combined with chemoradiotherapy as initial treatment for anaplastic thyroid cancer. Thyroid 29(11): 1615-1622, 2019. PMID: 31595822. DOI: 10.1089/thy.2019.0086
    OpenUrlCrossRef
  20. ↵
    1. Sherman EJ,
    2. Tsai CJ,
    3. Zhi WI,
    4. Fetten JV,
    5. Wu V,
    6. Ho AL,
    7. Riaz N,
    8. Pfister DG and
    9. Lee NY
    : Pilot study combining PD-L1 antibody durvalumab (D) with CTLA-4 antibody tremelimumab (T) and stereotactic body radiotherapy (SBRT) to treat metastatic anaplastic thyroid cancer (ATC). J Clin Oncol 37(Suppl 15): 6088, 2019. DOI: 10.1200/JCO.2019.37.15_suppl.6088
    OpenUrlCrossRef
  21. ↵
    1. Capdevila J,
    2. Wirth LJ,
    3. Ernst T,
    4. Ponce Aix S,
    5. Lin C-C,
    6. Ramlau R,
    7. Butler MO,
    8. Delord J-P,
    9. Gelderblom H,
    10. Ascierto PA,
    11. Fasolo A,
    12. Führer D,
    13. Hütter-Krönke ML,
    14. Forde PM,
    15. Wrona A,
    16. Santoro A,
    17. Sadow PM,
    18. Szpakowski S,
    19. Wu H,
    20. Bostel G,
    21. Faris J,
    22. Cameron S,
    23. Varga A and
    24. Taylor M
    : PD-1 blockade in anaplastic thyroid carcinoma. J Clin Oncol 38(23): 2620-2627, 2020. PMID: 32364844. DOI: 10.1200/JCO.19.02727
    OpenUrlCrossRefPubMed
  22. ↵
    1. Dierks C,
    2. Miething C,
    3. Thomusch O,
    4. von Bubnoff N and
    5. Duyster J
    : Lenvatinib and pembrolizumab as save and effective combination treatment in 8 patients with metastasized anaplastic (ATC) or poorly differentiated thyroid carcinoma (PDTC). Ann Oncol 29(Suppl 8): VIII646, 2018. DOI: 10.1093/annonc/mdy302.004
    OpenUrlCrossRef
  23. ↵
    1. Dierks C,
    2. Seufert J,
    3. Ruf J,
    4. Duyster J,
    5. Thomusch O and
    6. Miething C and
    7. Zielke A
    : 1915P The lenvatinib/pembrolizumab combination induces long lasting and complete responses in patients with metastatic anaplastic or poorly differentiated thyroid carcinoma: Results from a retrospective study and first results from the prospective phase II ATLEP trial. Ann Oncol 31(4): S1085, 2020. DOI: 10.1016/j.annonc.2020.08.1403
    OpenUrlCrossRef
PreviousNext
Back to top

In this issue

In Vivo
Vol. 35, Issue 1
January-February 2021
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on In Vivo.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Radiation to the Primary Tumor in Metastatic Anaplastic Thyroid Cancer
(Your Name) has sent you a message from In Vivo
(Your Name) thought you would like to see the In Vivo web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
10 + 1 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Radiation to the Primary Tumor in Metastatic Anaplastic Thyroid Cancer
TERESA AUGUSTIN, DMYTRO OLIINYK, JOSEFINE RAUCH, VIKTORIA FLORENTINE KOEHLER, CHRISTINE SPITZWEG, CLAUS BELKA, LUKAS KÄSMANN
In Vivo Jan 2021, 35 (1) 461-465; DOI: 10.21873/invivo.12279

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Radiation to the Primary Tumor in Metastatic Anaplastic Thyroid Cancer
TERESA AUGUSTIN, DMYTRO OLIINYK, JOSEFINE RAUCH, VIKTORIA FLORENTINE KOEHLER, CHRISTINE SPITZWEG, CLAUS BELKA, LUKAS KÄSMANN
In Vivo Jan 2021, 35 (1) 461-465; DOI: 10.21873/invivo.12279
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Conclusion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Prognostic Factors and Survival Score for Patients With Anaplastic Thyroid Carcinoma: A Retrospective Study from a Regional Registry
  • Google Scholar

More in this TOC Section

  • Surgical Treatment and Prognosis of Soft Tissue Sarcoma in Patients Aged 85 Years and Older
  • Neutrophil-to-Lymphocyte Ratio as a Biomarker for Postoperative Complications in Crohn’s Disease
  • IgA Nephropathy Associated With Infliximab Treatment in Patients With Crohn’s Disease: Study of IgA1 and IgA2 Expression in Glomeruli
Show more Clinical Studies

Similar Articles

Keywords

  • ATC
  • anaplastic thyroid cancer
  • metastatic
  • irradiation
  • survival
In Vivo

© 2025 In Vivo

Powered by HighWire